Application of caspase-independent apoptosis to molecular target therapy
| Project/Area Number |
15K11243
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 細胞死 / 分子標的治療 / PKC / オートファジー |
|---|
| Outline of Final Research Achievements |
Cell death includes not only necrosis and apoptosis, but also autophagic cell death. Safingol induces apoptosis in a caspase-independent manner. However, the role of autophagy in endoG-mediated apoptosis in oral squamous cell carcinoma (SCC) cells has not yet been investigated. Safingol induced apoptosis and autophagy in human oral SCC cells. The suppression of autophagy by autophagy inhibitors, such as 3-MA or bafilomycin A1 significantly augmented cell death caused by safingol, Autophagy played a protective role in endoG-mediated apoptosis, but did not induce autophagic cell death. The inhibitory effects of other anticancer agents on autophagy must be considered when they are used in combination with safingol in clinical trials.
|
Report
(4 results)
Research Products
(23 results)
